Valganciclovir

N/A

Report date: 2025/02/06 20:00:06
NME

Base Information

Drug NameValganciclovir
Drug Alias Namevalganciclovir
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVirus DNA polymerase inhibitors
TargetsVirus DNA polymerase
Therapy Area/IndicationsRejection of renal transplantationKidney DiseasesUveitis +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesSkiron Biosciences
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoWits Health Consortium (Pty) Ltd
Inactive CompaniesSkiron Biosciences
Active IndicationsRejection of renal transplantationKidney DiseasesCytomegalovirus Infections
Inactive IndicationsUveitis

Other Information

ATC CodeN/A
Related LinksN/A